| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HOWL | Common Stock | Exercise of in-the-money or at-the-money derivative security | $4.58K | +50.9K | +0.76% | $0.09 | 6.72M | Mar 27, 2025 | See Footnote | F1, F2, F3 |
| transaction | HOWL | Common Stock | Sale | -$4.61K | -4.39K | -0.07% | $1.05 | 6.72M | Mar 27, 2025 | See Footnote | F1, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HOWL | Warrant (Right to Buy) | Exercise of in-the-money or at-the-money derivative security | $0 | -8.03K | -100% | $0.00 | 0 | Mar 27, 2025 | Common Stock | 8.03K | $0.09 | See Footnote | F1, F5, F6 |
| transaction | HOWL | Warrant (Right to Buy) | Exercise of in-the-money or at-the-money derivative security | $0 | -42.8K | -100% | $0.00 | 0 | Mar 27, 2025 | Common Stock | 42.8K | $0.09 | See Footnote | F1, F5, F7 |
| Id | Content |
|---|---|
| F1 | On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares. |
| F2 | The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 640,121 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 2,410,771 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| F3 | MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| F4 | The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014, 639,659 by MPM OIF and 2,408,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| F5 | Immediately exercisable. |
| F6 | The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV 2014 and 4,016 by UBS Oncology. |
| F7 | The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014, 5,355 by MPM OIF and 18,744 by UBS Oncology. |